|1.||Lee, Jae Yeol: 4 articles (03/2014 - 07/2008)|
|2.||Cho, Sehyeon: 3 articles (03/2014 - 12/2013)|
|3.||Lee, Kyung-Tae: 3 articles (03/2014 - 12/2013)|
|4.||Rim, Hong-Kun: 3 articles (03/2014 - 12/2013)|
|5.||Choi, Doo Li: 2 articles (03/2014 - 12/2013)|
|6.||Choi, Hye-Eun: 2 articles (03/2014 - 12/2013)|
|7.||Jang, Sun Jeong: 2 articles (03/2014 - 12/2013)|
|8.||Rhim, Hyewhon: 2 articles (12/2013 - 07/2008)|
|9.||Shin, Dong-Hyun: 1 article (01/2014)|
|10.||Chung, Kyung-Sook: 1 article (01/2014)|
|1.||Ovarian Neoplasms (Ovarian Cancer)
12/15/2013 - "With respect to cell cycle arrest effect on A2780 and A2780-T cells, KYS05090 induced large proportion of sub-G1 phase in the cell cycle progression of A2780 and A2780-T, meaning the induction of cancer cell death instead of cell cycle arrest via blocking T-type Ca(2+) channel. "
07/15/2008 - "As a result, KYS05090, a most potent T-type Ca(2+) channel blocker, was found to be as potent as doxorubicin against some human cancer cells without acute toxicity. "
01/01/2014 - "It has been reported that [3-(1,1'-biphenyl-4-yl)-2-(1-methyl-5-dimethylamino-pentylamino)-3,4-dihydroquinazolin-4-yl]-N-benzylacetamide 2hydrochloride (KYS05090), a selective T-type Ca2+ channel blocker, reduces tumor volume and weight in the A549 xenograft model, but the molecular mechanism of cell death has not yet been elucidated. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
03/15/2014 - "The MTT assay results indicated that BK10040 was cytotoxic against human lung adenocarcinoma (A549) and pancreatic cancer (MiaPaCa2) cells in a dose-dependent manner with IC50 of 2.25 and 0.93μM, respectively, which is ca. 2-fold more potent than lead compound KYS05090 despite of its decreased T-type calcium channel blockade. "
|4.||Lung Neoplasms (Lung Cancer)
|2.||T-Type Calcium Channels (T-Type Calcium Channel)
|5.||Adenocarcinoma of lung
|1.||Heterologous Transplantation (Xenotransplantation)